secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALX ONCOLOGY HOLDINGS INC (ALXO)
CIK:        0001810182
Form:       8-K
Filed at:   2022-08-08T23:59:59+00:00
Accession:  0000950170-22-015504
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ALX Oncology Q2 net loss $32.9M ($0.81 EPS); FDA fast track and ODD for evorpacept
--------------------------------------------------------------------------------

- Net loss GAAP $32.9M ($0.81/share) vs $16.3M ($0.40) in Q2 2021; R&D spend $26.7M vs $11.2M.
- Cash/investments $324.2M sufficient to fund operations through Q4 2024.
- FDA granted Fast Track designation for evorpacept in 1st-line PD-L1+ HNSCC; ODD for AML.
- ASPEN-05 (AML) Phase 1 dose escalation completed; enrollment paused for dose optimization pending ASPEN-02 data.
- ASPEN-06 gastric/GEJ Phase 2 results expected 2023; ASPEN-07 (UC) initiation planned Q4 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810182/000095017022015504/0000950170-22-015504-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810182/000095017022015504/alxo-20220808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-015504

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer